Glivec to generic imatinib switch: <i>in vitro</i> comparative dissolution assessment, bioequivalence, safety, and tolerability of 400 mg imatinib tablets in healthy volunteers
Imatinib is currently considered the “gold standard” pharmacotherapy for chronic myelogenous leukemia (CML) at all stages and is most commonly used in the form of tablets taken orally.
Authors
- Tarun Kumar Dua (ORCID: https://orcid.org/0000-0001-5136-7564)
- Saurav Sarkar (ORCID: https://orcid.org/0000-0002-5706-9565)
- Paramita Paul (ORCID: https://orcid.org/0000-0002-8077-9530)
- Gouranga Nandi (ORCID: https://orcid.org/0000-0001-9571-3641)
- Ranabir Sahu (ORCID: https://orcid.org/0000-0002-2229-1019)
- Samir Das
Institutions
- North Bengal University (IN)
Publication Details
- Journal
- RSC Pharmaceutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5pm00099h
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00